Evidence mapPaperPMID 36160032Full record

ArticleGenetics research2022

Quantitative Expression of

Mehrnoush Rishehri, Tahereh Etemadi, Leila Pisheh, Ghazaleh Koufigar, Mansoureh Azadeh

Open access · goldAbstract read
In one paragraph

Article in Genetics research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Role ofPathophysiology : the official journal of the International Society for Pathophysiology · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Mehrnoush RishehriZist Fanavari Novin Biotechnology Institute, Isfahan, Iran.ORCID 0000-0002-9353-4751
Tahereh EtemadiZist Fanavari Novin Biotechnology Institute, Isfahan, Iran.
Leila PishehZist Fanavari Novin Biotechnology Institute, Isfahan, Iran.ORCID 0000-0002-1264-6146
Ghazaleh KoufigarZist Fanavari Novin Biotechnology Institute, Isfahan, Iran.
Mansoureh AzadehZist Fanavari Novin Biotechnology Institute, Isfahan, Iran.ORCID 0000-0003-2031-4640
Agricultural Biotechnology Research Institute of Iran · IRIslamic Azad University Rasht Branch · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is one of the leading cancers in the world, which has become an increasing serious problem. In this context, reports demonstrate that some long noncoding RNAs (lncRNAs) play significant regulatory roles in breast tumorigenesis and BC progression via various pathways and act as endogenous RNAs. Finding their dysregulation in cancer and evaluating their interaction with other molecules, such as short noncoding RNAs "microRNA (miRNAs)" as well as various genes, are the most important parts in cancer diagnostics. In this study, after performing GSEA and microarray analysis on the GSE71053 dataset, a new ceRNA network of CCDC18-AS1, LINC01343, hsa-miR4462, and

Indexed as

Breast NeoplasmsMicroRNAsRNA, Long NoncodingBiomarkersBiomarkers, TumorCarcinogenesisCell ProliferationComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansBiomarkersBiomarkers, TumorMicroRNAsRNA, Long Noncoding

Identifiers

PMID36160032
PMCPMC9484965
OpenAlexW4296555374

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.